105 related articles for article (PubMed ID: 10203029)
1. Cellular immunity and target cell susceptibility in persons with repeated HIV-1 exposure.
Akridge R; Hladik F; Markee J; Alef C; Kelley H; Collier A; Collier A; McElrath MJ
Immunol Lett; 1999 Mar; 66(1-3):15-9. PubMed ID: 10203029
[TBL] [Abstract][Full Text] [Related]
2. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects.
Goh WC; Markee J; Akridge RE; Meldorf M; Musey L; Karchmer T; Krone M; Collier A; Corey L; Emerman M; McElrath MJ
J Infect Dis; 1999 Mar; 179(3):548-57. PubMed ID: 9952360
[TBL] [Abstract][Full Text] [Related]
3. Impact of highly active antiretroviral treatment on expression of HIV-1 coreceptors and ligand levels in peripheral blood from HIV-1 infected patients in China.
Fang J; Bai S; Wu L; Zhu X; Yao X; Jin C; Wang C
J Int Med Res; 2013 Oct; 41(5):1560-9. PubMed ID: 24043708
[TBL] [Abstract][Full Text] [Related]
4. The number of CCR5 expressing CD4+ T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: a cross-sectional study.
Meijerink H; Indrati AR; van Crevel R; Joosten I; Koenen H; van der Ven AJ
BMC Infect Dis; 2014 Dec; 14():683. PubMed ID: 25495598
[TBL] [Abstract][Full Text] [Related]
5. Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32.
Henrich TJ; Hanhauser E; Hu Z; Stellbrink HJ; Noah C; Martin JN; Deeks SG; Kuritzkes DR; Pereyra F
AIDS; 2015 May; 29(8):867-76. PubMed ID: 25730507
[TBL] [Abstract][Full Text] [Related]
6. Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells.
Agrawal L; Lu X; Qingwen J; VanHorn-Ali Z; Nicolescu IV; McDermott DH; Murphy PM; Alkhatib G
J Virol; 2004 Mar; 78(5):2277-87. PubMed ID: 14963124
[TBL] [Abstract][Full Text] [Related]
7. Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice.
Ye C; Wang W; Cheng L; Li G; Wen M; Wang Q; Zhang Q; Li D; Zhou P; Su L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881659
[TBL] [Abstract][Full Text] [Related]
8. The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression.
Paxton WA; Kang S; Koup RA
AIDS Res Hum Retroviruses; 1998 Apr; 14 Suppl 1():S89-92. PubMed ID: 9581891
[TBL] [Abstract][Full Text] [Related]
9. Partial resistance to infection by R5X4 primary HIV type 1 isolates in an exposed-uninfected individual homozygous for CCR5 32-base pair deletion.
Xiao L; Weiss SH; Qari SH; Rudolph D; Zhao C; Denny TN; Hodge T; Lal RB
AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1201-8. PubMed ID: 10480633
[TBL] [Abstract][Full Text] [Related]
10. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection.
de Roda Husman AM; Blaak H; Brouwer M; Schuitemaker H
J Immunol; 1999 Oct; 163(8):4597-603. PubMed ID: 10510404
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of CCR5 on activated CD4 T cells in HIV-infected Indians.
Dubey S; Khalid M; Wesley C; Khan SA; Wanchu A; Jameel S
J Clin Virol; 2008 Sep; 43(1):25-31. PubMed ID: 18462992
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X
Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597
[TBL] [Abstract][Full Text] [Related]
13. Differential Ability of Primary HIV-1 Nef Isolates To Downregulate HIV-1 Entry Receptors.
Toyoda M; Ogata Y; Mahiti M; Maeda Y; Kuang XT; Miura T; Jessen H; Walker BD; Brockman MA; Brumme ZL; Ueno T
J Virol; 2015 Sep; 89(18):9639-52. PubMed ID: 26178998
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 co-receptor expression and epithelial immune cells of the cervix in asymptomatic women attending a genitourinary medicine clinic.
McClure CP; Bowman CA; Geary I; Ryan C; Ball JK; Eley A
HIV Med; 2013 Feb; 14(2):108-14. PubMed ID: 23171088
[TBL] [Abstract][Full Text] [Related]
15. Sex, alloimmunisation, and susceptibility to HIV infection.
Quayle AJ; Fidel P; Rosenberg ES
Lancet; 2004 Feb; 363(9408):503-4. PubMed ID: 14975608
[No Abstract] [Full Text] [Related]
16. Increase in activated CD4+ lymphocytes with CCR5 and CXCR4 in HIV type 1-infected persons.
Auewarakul P; Sangsiriwut K; Pattanapanyasat K; Suwanagool S; Wasi C
AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1403-4. PubMed ID: 10515156
[No Abstract] [Full Text] [Related]
17. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage.
Xiao L; Owen SM; Goldman I; Lal AA; deJong JJ; Goudsmit J; Lal RB
Virology; 1998 Jan; 240(1):83-92. PubMed ID: 9448692
[TBL] [Abstract][Full Text] [Related]
18. Chemokine/CD4 receptor density ratios correlate with HIV replication in lymph node and peripheral blood of HIV-infected individuals.
Nokta MA; Li XD; Nichols J; Mallen M; Pou A; Asmuth D; Pollard RB
AIDS; 2001 Jan; 15(2):161-9. PubMed ID: 11216923
[TBL] [Abstract][Full Text] [Related]
19. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals.
Ostrowski MA; Justement SJ; Catanzaro A; Hallahan CA; Ehler LA; Mizell SB; Kumar PN; Mican JA; Chun TW; Fauci AS
J Immunol; 1998 Sep; 161(6):3195-201. PubMed ID: 9743388
[TBL] [Abstract][Full Text] [Related]
20. Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission.
Hladik F; Liu H; Speelmon E; Livingston-Rosanoff D; Wilson S; Sakchalathorn P; Hwangbo Y; Greene B; Zhu T; McElrath MJ
J Virol; 2005 Sep; 79(18):11677-84. PubMed ID: 16140745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
